Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Apolipoprotein E controls cerebrovascular integrity via cyclophilin A

Nature volume 485, pages 512–516 (2012)Cite this article

Subjects

An Author Correction to this article was published on 05 May 2023

This article has been updated

Abstract

Human apolipoprotein E has three isoforms: APOE2, APOE3 and APOE41. APOE4 is a major genetic risk factor for Alzheimer’s disease2,3 and is associated with Down’s syndrome dementia and poor neurological outcome after traumatic brain injury and haemorrhage3. Neurovascular dysfunction is present in normal APOE4 carriers4,5,6 and individuals with APOE4-associated disorders3,7,8,9,10. In mice, lack of Apoe leads to blood–brain barrier (BBB) breakdown11,12, whereas APOE4 increases BBB susceptibility to injury13. How APOE genotype affects brain microcirculation remains elusive. Using different APOE transgenic mice, including mice with ablation and/or inhibition of cyclophilin A (CypA), here we show that expression of APOE4 and lack of murine Apoe, but not APOE2 and APOE3, leads to BBB breakdown by activating a proinflammatory CypA–nuclear factor-κB–matrix-metalloproteinase-9 pathway in pericytes. This, in turn, leads to neuronal uptake of multiple blood-derived neurotoxic proteins, and microvascular and cerebral blood flow reductions. We show that the vascular defects in Apoe-deficient and APOE4-expressing mice precede neuronal dysfunction and can initiate neurodegenerative changes. Astrocyte-secreted APOE3, but not APOE4, suppressed the CypA–nuclear factor-κB–matrix-metalloproteinase-9 pathway in pericytes through a lipoprotein receptor. Our data suggest that CypA is a key target for treating APOE4-mediated neurovascular injury and the resulting neuronal dysfunction and degeneration.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: CypA deficiency or inhibition reverses BBB breakdown in Apoe − /− and APOE4 mice.
Figure 2: CypA activates the NF-κB–MMP9 pathway causing BBB breakdown in Apoe − /− and APOE4 mice.
Figure 3: CypA ablation or inhibition reverses microvascular and CBF reductions in Apoe − /− and APOE4 mice.
Figure 4: APOE isoform-specific regulation of CypA–NF-κB–MMP9 pathway in pericytes.
Figure 5: Vascular defects in Apoe − /− and APOE4 mice precede neuronal dysfunction.

Similar content being viewed by others

Change history

References

  1. Mahley, R. W., Weisgraber, K. H. & Huang, Y. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer’s disease to AIDS. J. Lipid Res. 50 (Suppl.). S183–S188 (2009)

    Article  PubMed  PubMed Central  Google Scholar 

  2. Kim, J., Basak, J. M. & Holtzman, D. M. The role of apolipoprotein E in Alzheimer’s disease. Neuron 63, 287–303 (2009)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Verghese, P. B., Castellano, J. M. & Holtzman, D. M. Apolipoprotein E in Alzheimer’s disease and other neurological disorders. Lancet Neurol. 10, 241–252 (2011)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Thambisetty, M., Beason-Held, L., An, Y., Kraut, M. A. & Resnick, S. M. APOE ε4 genotype and longitudinal changes in cerebral blood flow in normal aging. Arch. Neurol. 67, 93–98 (2010)

    Article  PubMed  PubMed Central  Google Scholar 

  5. Sheline, Y. I. et al. APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Aβ42. J. Neurosci. 30, 17035–17040 (2010)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Reiman, E. M. et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia. Proc. Natl Acad. Sci. USA 101, 284–289 (2004)

    Article  ADS  CAS  PubMed  Google Scholar 

  7. Zlokovic, B. V. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nature Rev. Neurosci. 12, 723–738 (2011)

    Article  CAS  Google Scholar 

  8. Snowdon, D. A. et al. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. J. Am. Med. Assoc. 277, 813–817 (1997)

    Article  CAS  Google Scholar 

  9. Vermeer, S. E. et al. Silent brain infarcts and the risk of dementia and cognitive decline. N. Engl. J. Med. 348, 1215–1222 (2003)

    Article  PubMed  Google Scholar 

  10. Ruitenberg, A. et al. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann. Neurol. 57, 789–794 (2005)

    Article  PubMed  Google Scholar 

  11. Methia, N. et al. ApoE deficiency compromises the blood–brain barrier especially after injury. Mol. Med. 7, 810–815 (2001)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Hafezi-Moghadam, A., Thomas, K. L. & Wagner, D. D. ApoE deficiency leads to a progressive age-dependent blood–brain barrier leakage. Am. J. Physiol. Cell Physiol. 292, C1256–C1262 (2007)

    Article  CAS  PubMed  Google Scholar 

  13. Nishitsuji, K., Hosono, T., Nakamura, T., Bu, G. & Michikawa, M. Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood–brain barrier model. J. Biochem. 286, 17536–17542 (2011)

    CAS  Google Scholar 

  14. Bell, R. D. et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 68, 409–427 (2010)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Armulik, A. et al. Pericytes regulate the blood–brain barrier. Nature 468, 557–561 (2010)

    Article  ADS  CAS  PubMed  Google Scholar 

  16. Sullivan, P. M. et al. Reduced levels of human apoE4 protein in an animal model of cognitive impairment. Neurobiol. Aging 32, 791–801 (2011)

    Article  CAS  PubMed  Google Scholar 

  17. Satoh, K. et al. Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nature Med. 15, 649–656 (2009)

    Article  CAS  PubMed  Google Scholar 

  18. Jin, Z. G. et al. Cyclophilin A is a proinflammatory cytokine that activates endothelial cells. Arterioscler. Thromb. Vasc. Biol. 24, 1186–1191 (2004)

    Article  CAS  PubMed  Google Scholar 

  19. Handschumacher, R. E., Harding, M. W., Rice, J., Drugge, R. J. & Speicher, D. W. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 226, 544–547 (1984)

    Article  ADS  CAS  PubMed  Google Scholar 

  20. Begley, D. J. et al. Permeability of the blood–brain barrier to the immunosuppressive cyclic peptide cyclosporin A. J. Neurochem. 55, 1222–1230 (1990)

    Article  CAS  PubMed  Google Scholar 

  21. Grammas, P. Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer’s disease. J. Neuroinflammation 8, 26 (2011)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Paul, J., Strickland, S. & Melchor, J. P. Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer’s disease. J. Exp. Med. 204, 1999–2008 (2007)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Zhong, Z. et al. Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J. Clin. Invest. 119, 3437–3449 (2009)

    ADS  CAS  PubMed  PubMed Central  Google Scholar 

  24. Candelario-Jalil, E. et al. Matrix metalloproteinases are associated with increased blood–brain barrier opening in vascular cognitive impairment. Stroke 42, 1345–1350 (2011)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Garcia-Alloza, M. et al. Matrix metalloproteinase inhibition reduces oxidative stress associated with cerebral amyloid angiopathy in vivo in transgenic mice. J. Neurochem. 109, 1636–1647 (2009)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Jaeger, L. B. et al. Testing the neurovascular hypothesis of Alzheimer’s disease: LRP-1 antisense reduces blood–brain barrier clearance, increases brain levels of amyloid-β protein, and impairs cognition. J. Alzheimers Dis. 17, 553–570 (2009)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Yang, Y., Lu, N., Zhou, J., Chen, Z. N. & Zhu, P. Cyclophilin A up-regulates MMP-9 expression and adhesion of monocytes/macrophages via CD147 signalling pathway in rheumatoid arthritis. Rheumatology 47, 1299–1310 (2008)

    Article  CAS  PubMed  Google Scholar 

  28. Deane, R. et al. apoE isoform-specific disruption of amyloid β peptide clearance from mouse brain. J. Clin. Invest. 118, 4002–4013 (2008)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Masliah, E. et al. Neurodegeneration and cognitive impairment in apoE-deficient mice is ameliorated by infusion of recombinant apoE. Brain Res. 751, 307–314 (1997)

    Article  CAS  PubMed  Google Scholar 

  30. Zipser, B. D. et al. Microvascular injury and blood–brain barrier leakage in Alzheimer’s disease. Neurobiol. Aging 28, 977–986 (2007)

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank the National Institute of Health for grants R37NS34467 (B.V.Z.); R37AG23084 (B.V.Z.); RO1AG039452 (B.V.Z.); and R37AG13956 (D.M.H.) used to support this study.

Author information

Authors and Affiliations

  1. Center for Neurodegenerative and Vascular Brain Disorders, University of Rochester Medical Center, Rochester, 14642, New York, USA

    Robert D. Bell, Ethan A. Winkler, Itender Singh, Abhay P. Sagare, Rashid Deane, Zhenhua Wu, Jan Sallstrom & Berislav V. Zlokovic

  2. Aab Cardiovascular Research Institute, University of Rochester Medical Center, Rochester, 14642, New York, USA

    Robert D. Bell & Bradford C. Berk

  3. Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, Saint Louis, 63110, Missouri, USA

    David M. Holtzman

  4. Division of Vascular Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm SE-171 77, Sweden,

    Christer Betsholtz & Annika Armulik

  5. Institute of Neuropathology, University Hospital Zürich, CH-8091, Zürich, Switzerland ,

    Annika Armulik

  6. Zilkha Neurogenetic Institute and Department of Physiology and Biophysics, Center for Neurodegeneration and Regeneration, University of Southern California, Keck School of Medicine, Los Angeles, 90089, California, USA

    Berislav V. Zlokovic

Authors
  1. Robert D. Bell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ethan A. Winkler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Itender Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Abhay P. Sagare
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rashid Deane
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhenhua Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. David M. Holtzman
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Christer Betsholtz
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Annika Armulik
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jan Sallstrom
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Bradford C. Berk
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Berislav V. Zlokovic
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

R.D.B. designed and performed experiments, analysed data and contributed to writing the paper. E.A.W. designed and performed experiments. I.S. performed experiments. A.P.S. performed CBF experiments. R.D. designed experiments and analysed data. Z.W. gathered pilot data. D.M.H. provided guidance and edited the paper. C.B. designed experiments and edited the paper. A.A. performed pilot cadaverine studies. J.S. generated pilot data. B.C.B. provided guidance and edited the paper. B.V.Z. designed experiments, analysed data and wrote the paper.

Corresponding author

Correspondence to Berislav V. Zlokovic.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Information

This file contains Supplementary Figures 1-15, Supplementary Materials and Methods, Supplementary Discussion, Supplementary Tables 1-3 and Supplementary References. (PDF 1515 kb)

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bell, R., Winkler, E., Singh, I. et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485, 512–516 (2012). https://doi.org/10.1038/nature11087

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nature11087

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing